TNFRSF8 and lymphoma: Nonetheless, with a CR rate of 75% as well as an OS rate and PFS rate at one year of 83% and 67%, respectively, in a patient group that usually has an adverse prognosis, the novel approach warrants further evaluation as an HDCT regimen before ASCT in patients with CD30 positive lymphomas.